Top

Journal of Cancer Research and Clinical Oncology

Published in:

15-07-2022 | Lung Cancer | Research

Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma

Authors: Peng Li, Shuyu Che, Yingxue Qi, Ningning Luo, Qiuju Lin, Xiaofeng Zhu, Yunpeng Xuan, Mengmeng Li, Jinlong Li, Minghui Ge, Tingting Sun, Chuang Qi, Yongjie Wang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2023

Abstract

Background

The incidence of lung cancer tends to be younger, and adenocarcinoma is the main histological type. Even patients with the same tumor type may have significant differences in clinical features, tumor microenvironment and genomic background at different ages. Immune checkpoint inhibitors (ICIs) have been shown to improve clinical outcomes in patients with lung adenocarcinoma (LUAD). However, differences in ICI efficacy between older and younger patients are unknown. Our study aimed to explore the relationship between age and immunotherapy in LUAD.

Methods

In our study, 1313 resected LUAD patients in our hospital were divided into young (age ≤ 50) and old groups (age > 50), and the clinical characteristic differences between them were analyzed. Of these, next-generation sequencing (NGS) was performed on the 311 cases. In addition, immune-related signatures of 508 LUAD patients were analyzed by TCGA RNA expression data. Then, we validated genomic and clinical information of 270 LUAD samples in the MSKCC cohort.

Results

ERBB2 and EGFR gene mutations were significantly different between the two groups, and the gene mutation number in the old group was significantly higher than that in the young group. In addition, immune-related signatures of LUAD patients were analyzed by TCGA RNA expression data, which indicated that the patients in the old group might have a better immune microenvironment. Then, we validated the MSKCC cohort and found that the TMB of the old group was significantly higher than that of the young group, and the OS of immunotherapy was longer in the old group.

Conclusion

Our study was the first to analyze the differences in the genomic landscape and immune-related biomarkers between the young and old groups of LUAD patients and found that the old group had a better efficacy of immunotherapy, providing a reference for the study design and treatment of patients with LUAD.

Available only for authorised users

Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ et al (2016) Lung cancer in the very young: treatment and survival in the national cancer data base. J Thorac Oncol 11(7):1121–1131. https://doi.org/10.1016/j.jtho.2016.03.023CrossRefPubMed

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 27(8):2930–2940. https://doi.org/10.1172/JCI91190CrossRef

Büttner R, Gosney JR, Skov BG et al (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35(34):3867–3876. https://doi.org/10.1200/JCO.2017.74.7642CrossRefPubMed

Cai L, Chen Y, Tong X, Wu X, Bao H, Shao Y et al (2021) The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients. Int J Cancer. https://doi.org/10.1002/ijc.33583CrossRefPubMedPubMedCentral

Camidge DR, Doebele RC, Kerr KM (2019) Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol 16(6):341–355. https://doi.org/10.1038/s41571-019-0173-9CrossRefPubMed

Cao J, Li J, Yang X, Li P, Yao Z, Han D et al (2021) Transcriptomics analysis for the identification of potential age-related genes and cells associated with three major urogenital cancers. Sci Rep 11(1):641. https://doi.org/10.1038/s41598-020-80065-yCrossRefPubMedPubMedCentral

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, CheckMate 026 Investigators et al (2017) First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415–2426. https://doi.org/10.1056/NEJMoa1613493CrossRefPubMedPubMedCentral

Casaluce F, Sgambato A, Maione P, Spagnuolo A, Gridelli C (2018) Lung cancer, elderly and immune checkpoint inhibitors. J Thorac Dis 10(Suppl 13):S1474–S1481. https://doi.org/10.21037/jtd.2018.05.90CrossRefPubMedPubMedCentral

Charvat H, Sasazuki S, Shimazu T, Budhathoki S, Inoue M, Iwasaki M, JPHC Study Group et al (2018) Development of a risk prediction model for lung cancer: The Japan Public Health Center-based Prospective Study. Cancer Sci 109(3):854–862. https://doi.org/10.1111/cas.13509CrossRefPubMedPubMedCentral

Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338CrossRefPubMed

Chen S, Zhou Y, Chen Y, Gu J (2018) fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. https://doi.org/10.1093/bioinformatics/bty560CrossRefPubMedPubMedCentral

Chen J, Yang H, Teo ASM et al (2020) Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 52(2):177–186. https://doi.org/10.1038/s41588-019-0569-6CrossRefPubMed

Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML et al (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18. https://doi.org/10.1186/s40425-017-0215-8CrossRefPubMedPubMedCentral

Davoli T, Uno H, Wooten EC, Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. https://doi.org/10.1126/science.aaf8399CrossRefPubMedPubMedCentral

Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O (2018) Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer 6(1):26. https://doi.org/10.1186/s40425-018-0336-8CrossRefPubMedPubMedCentral

Gu Y, Zhang J, Zhou Z, Liu D, Zhu H, Wen J et al (2020) Metastasis patterns and prognosis of octogenarians with NSCLC: a population-based study. Aging Dis 11(1):82–92. https://doi.org/10.14336/AD.2019.0414CrossRefPubMedPubMedCentral

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582–588. https://doi.org/10.1093/annonc/mdz011CrossRefPubMedPubMedCentral

Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104. https://doi.org/10.1056/NEJMoa1801946CrossRefPubMedPubMedCentral

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7CrossRefPubMed

Hwang KB, Lee IH, Li H, Won DG, Hernandez-Ferrer C, Negron JA et al (2019) Comparative analysis of whole-genome sequencing pipelines to minimize false negative findings. Sci Rep 9(1):3219. https://doi.org/10.1038/s41598-019-39108-2CrossRefPubMedPubMedCentral

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558. https://doi.org/10.1038/s41591-018-0136-1CrossRefPubMedPubMedCentral

Kim H, Kwon HJ, Kim ES et al (2021) Comparison of the predictive power of a combination versus individual biomarker testing in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Res Treat. https://doi.org/10.4143/crt.2021.583.httpCrossRefPubMedPubMedCentral

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R et al (2016) VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 44(11):e108. https://doi.org/10.1093/nar/gkw227CrossRefPubMedPubMedCentral

Li Q, Wang K (2017) InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet 100(2):267–280. https://doi.org/10.1016/j.ajhg.2017.01.004CrossRefPubMedPubMedCentral

Liang Y, Hou H, Jiang M, Zhang C, Liu D, Zhang X (2020) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 23(4):239–246. https://doi.org/10.3779/j.issn.1009-3419.2020.101.17CrossRefPubMed

Liu L, Liu J, Shao D, Deng Q, Tang H, Liu Z et al (2017) Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. Cancer Sci 108(12):2487–2494. https://doi.org/10.1111/cas.13410CrossRefPubMedPubMedCentral

Liu B, Quan X, Xu C et al (2019) Lung cancer in young adults aged 35 years or younger: a full-scale analysis and review. J Cancer 10(15):3553–3559. https://doi.org/10.7150/jca.27490CrossRefPubMedPubMedCentral

Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI (2022) Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 13:823618. https://doi.org/10.3389/fimmu.2022.823618CrossRefPubMedPubMedCentral

Naltet C, Besse B (2021) Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. Transl Lung Cancer Res 10(6):3014–3028. https://doi.org/10.21037/tlcr-20-1239CrossRefPubMedPubMedCentral

Ettinger DS, Wood DE, Aisner DL, et al (2022) Non-small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025CrossRefPubMed

Newman AM, Bratman SV, Stehr H, Lee LJ, Liu CL, Diehn M et al (2014) FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics 30(23):3390–3393. https://doi.org/10.1093/bioinformatics/btu549CrossRefPubMedPubMedCentral

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J et al (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15(10):1657–1669. https://doi.org/10.1016/j.jtho.2020.06.015CrossRefPubMed

Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198–211. https://doi.org/10.1016/S1470-2045(20)30641-0CrossRefPubMed

Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556–560. https://doi.org/10.1038/s41586-019-1906-8CrossRefPubMed

Prat A, Navarro A, Paré L et al (2017) Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res 77(13):3540–3550. https://doi.org/10.1158/0008-5472 (CAN-16-3556)CrossRefPubMed

Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y et al (2021) Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun 12(1):6770. https://doi.org/10.1038/s41467-021-27022-zCrossRefPubMedPubMedCentral

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, IMpower150 Study Group et al (2019a) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7(5):387–401. https://doi.org/10.1016/S2213-2600(19)30084-0CrossRefPubMed

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2019b) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537–546. https://doi.org/10.1200/JCO.18.00149CrossRefPubMed

Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K et al (2019c) Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer 116:137–147. https://doi.org/10.1016/j.ejca.2019.05.008CrossRefPubMed

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR (2016) Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol 2(3):313–320. https://doi.org/10.1001/jamaoncol.2015.4482CrossRefPubMedPubMedCentral

Sanmamed MF, Nie X, Desai SS et al (2021) A burned-Out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov 11(7):1700–1715. https://doi.org/10.1158/2159-8290.CD-20-0962CrossRefPubMedPubMedCentral

Shah Y, Verma A, Marderstein AR, White J, Bhinder B, Garcia Medina JS et al (2021) Pan-cancer analysis reveals molecular patterns associated with age. Cell Rep 37(10):110100. https://doi.org/10.1016/j.celrep.2021.110100CrossRefPubMed

Soh J, Hamada A, Fujino T, Mitsudomi T (2021) Perioperative therapy for non-small cell lung cancer with immune checkpoint inhibitors. Cancers (basel) 13(16):4035. https://doi.org/10.3390/cancers13164035CrossRefPubMed

Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM et al (2019) Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). J Thorac Oncol 14(9):1628–1639. https://doi.org/10.1016/j.jtho.2019.05.010CrossRefPubMed

Suidan AM, Roisman L, Belilovski Rozenblum A et al (2019) Lung cancer in young patients: higher rate of driver mutations and brain involvement, but better survival. J Glob Oncol 5:1–8. https://doi.org/10.1200/JGO.18.00216CrossRefPubMed

Talevich E, Shain AH, Botton T, Bastian BC (2016) CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol 12(4):e1004873. https://doi.org/10.1371/journal.pcbi.1004873CrossRefPubMedPubMedCentral

Tanaka K, Hida T, Oya Y et al (2017) Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer 123(10):1731–1740. https://doi.org/10.1002/cncr.30539CrossRefPubMed

Tang S, Qin C, Hu H et al (2022) Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 11(3):320. https://doi.org/10.3390/cells11030320CrossRefPubMedPubMedCentral

Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G (2015) Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol 5:113. https://doi.org/10.3389/fonc.2015.00113CrossRefPubMedPubMedCentral

Tian P, Liu Y, Zeng H et al (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 146(4):935–944. https://doi.org/10.1007/s00432-019-03116-6CrossRefPubMed

US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M et al (2021) Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325(10):962–970. https://doi.org/10.1001/jama.2021.1117

Vitiello GA, Bowler TG, Liu M, Medina BD, Zhang JQ, Param NJ et al (2019) Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Invest 129(5):1863–1877. https://doi.org/10.1172/JCI124108CrossRefPubMedPubMedCentral

Wang Y, Chen J, Ding W, Yan B, Gao Q, Zhou J (2015) Clinical features and gene mutations of lung cancer patients 30 years of age or younger. PLoS ONE 10(9):e0136659. https://doi.org/10.1371/journal.pone.0136659CrossRefPubMedPubMedCentral

Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW et al (2019) Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS. SSO and TOS. Ann Oncol 30(2):171–210. https://doi.org/10.1093/annonc/mdy554CrossRefPubMed

Yang B, Li J, Li F et al (2019) Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients. Cancer Med 8(4):1350–1358. https://doi.org/10.1002/cam4.1839CrossRefPubMedPubMedCentral

Ye Y, Jing Y, Li L et al (2020) Sex-associated molecular differences for cancer immunotherapy. Nat Commun 11(1):1779. https://doi.org/10.1038/s41467-020-15679-xCrossRefPubMedPubMedCentral

Zhang C, Zhang J, Xu FP, Wang YG, Xie Z, Su J et al (2019a) Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol 14(11):1912–1923. https://doi.org/10.1016/j.jtho.2019.07.031CrossRefPubMedPubMedCentral

Zhang L, Sun L, Yu J, Shan F, Zhang K, Pang X et al (2019b) Comparison of immune checkpoint inhibitors between older and younger patients with advanced or metastatic lung cancer: a systematic review and meta-analysis. Biomed Res Int 2019:9853701. https://doi.org/10.1155/2019/9853701CrossRefPubMedPubMedCentral

Zhang QJ, Luan JC, Song LB et al (2021) Age-related differences in molecular profiles for immune checkpoint blockade therapy. Front Immunol 12:657575. https://doi.org/10.3389/fimmu.2021.657575CrossRefPubMedPubMedCentral

Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R et al (2022) Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 23(2):220–233. https://doi.org/10.1016/S1470-2045(21)00650-1CrossRefPubMed

Zhuo H, Zhao Y, Cheng X, Xu M, Wang L, Lin L et al (2019) Tumor endothelial cell-derived cadherin-2 promotes angiogenesis and has prognostic significance for lung adenocarcinoma. Mol Cancer 18(1):34. https://doi.org/10.1186/s12943-019-0987-1CrossRefPubMedPubMedCentral

Title: Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma
Authors: Peng Li
Shuyu Che
Yingxue Qi
Ningning Luo
Qiuju Lin
Xiaofeng Zhu
Yunpeng Xuan
Mengmeng Li
Jinlong Li
Minghui Ge
Tingting Sun
Chuang Qi
Yongjie Wang
Publication date: 15-07-2022
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Biomarkers
Checkpoint Inhibitors
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04195-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2023

Willingness, preferences, barriers, and facilitators of a multimodal supportive care intervention including exercise, nutritional and psychological approach in patients with cancer: a cross-sectional study

How can counselling by family physicians on nutrition and physical activity be improved: trends from a survey in Germany

Optical coherence tomography and convolutional neural networks can differentiate colorectal liver metastases from liver parenchyma ex vivo

Anticancer bioactivity of zerumbone on pediatric rhabdomyosarcoma cells

Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model

Nutrition and physical activity in cancer patients: a survey on their information sources

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage